Table 2

Antitumor efficacy among patients with BCC treated with PD-1 inhibition

All patients (n=29)Locally advanced (n=20)Metastatic disease (n=9)
Investigator assessed best overall response—no (%)
 Complete response (CR)4 (13.8)3 (15.0)1 (11.1)
 Partial response (PR)5 (17.2)4 (20.0)1 (11.1)
 Stable disease (SD)9 (31.0)6 (30.0)3 (33.3)
 Progressive disease9 (31.0)5 (25.0)4 (44.4)
 Could not be evaluated2 (6.9)2 (10.0)0 (0.0)
Objective response rate (PR +CR)31.0%35.0%22.2%
Disease control rate (SD +PR + CR)62.1%65.0%55.5%
  • BCC, basal cell carcinoma.